Drug Search Results
Using advanced filters...
Advanced Search [+]

HEC-169096

Alternative Names: HEC-169096, HEC 169096, HEC169096
Latest Update: 2022-10-27
Latest Update Note: Clinical Trial Update

Product Description

HEC-169096 is a drug candidate from Sunshine Lake Pharma for the treatment of advanced solid tumors. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05451602)

Mechanisms of Action: RET Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Sunshine Lake Pharma
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for HEC-169096

Countries in Clinic: China

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Non-Small-Cell Lung Cancer|Small Cell Lung Cancer|Thyroid Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

HEC169096-ST-101

P2

Recruiting

Thyroid Cancer|Small Cell Lung Cancer|Non-Small-Cell Lung Cancer

2025-07-30

57%

Recent News Events

Date

Type

Title